Brain metabolic patterns in patients with suspected non-Alzheimer’s pathophysiology (SNAP) and Alzheimer’s disease (AD): is [18F] FDG a specific biomarker in these patients?

Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer’s disease patients: A CSF and FDG PET study

(2018) Agostino Chiaravalloti et al.   BRAIN RESEARCH

Coupled Imaging with [18F]FBB and [18F]FDG in AD Subjects Show a Selective Association Between Amyloid Burden and Cortical Dysfunction in the Brain

(2018) Agostino Chiaravalloti et al.   MOLECULAR IMAGING AND BIOLOGY

Long Night's Journey into the Day: Amyloid-β Imaging in Alzheimer's Disease

(2018) Victor L. Villemagne et al.   JOURNAL OF ALZHEIMERS DISEASE

Functional correlates of TSH, fT3 and fT4 in Alzheimer disease: a F-18 FDG PET/CT study

(2017) Agostino Chiaravalloti et al.   Scientific Reports

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non–Alzheimer Disease Pathophysiology

(2017) Stefanie Schreiber et al.   JAMA Neurology

APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s Disease

(2017) Timothy J. Hohman et al.   PLoS One

Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers

(2016) Mohamed Reda Bensaïdane et al.   JOURNAL OF ALZHEIMERS DISEASE

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

(2016) Samantha C Burnham et al.   LANCET NEUROLOGY

Suspected non-Alzheimer disease pathophysiology — concept and controversy

(2016) Clifford R. Jack et al.   Nature Reviews Neurology

Precuneus and Cingulate Cortex Atrophy and Hypometabolism in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: MRI and18F-FDG PET Quantitative Analysis Using FreeSurfer

(2015) Matthieu Bailly et al.   Biomed Research International

Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine

(2013) Jan Booij et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

(2013) C. M. Roe et al.   NEUROLOGY

Preclinical AD predicts decline in memory and executive functions in subjective complaints

(2013) A. C. van Harten et al.   NEUROLOGY

Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People

(2013) Miranka Wirth et al.   JAMA Neurology

Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer’s disease

(2012) Ranjan Duara et al.   Alzheimers & Dementia

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

(2011) Victor L. Villemagne et al.   ANNALS OF NEUROLOGY

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

(2011) Clifford R. Jack et al.   ANNALS OF NEUROLOGY

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

(2011) Heiko Braak et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The principled control of false positives in neuroimaging

(2009) Craig M. Bennett et al.   Social Cognitive and Affective Neuroscience

Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias

(2008) L. Mosconi et al.   JOURNAL OF NUCLEAR MEDICINE